Susquehanna International Group’s LENZ Therapeutics LENZ Stock Holding History

Susquehanna International Group’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.01M	Buy	110,304 +42,582	+63%	+$598K	﹤0.01%	7852
2025 Q4	$1.08M	Buy	67,722 +17,171	+34%	+$500K	﹤0.01%	6996
2025 Q3	$2.35M	Buy	50,551 +28,366	+128%	+$1.04M	﹤0.01%	5442
2025 Q2	$650K	Buy	22,185 +5,869	+36%	+$160K	﹤0.01%	8553
2025 Q1	$419K	Buy	16,316 +8,300	+104%	+$204K	﹤0.01%	9300
2024 Q4	$231K	Buy	+8,016	New	+$244K	﹤0.01%	10393
2024 Q1	–	Sell	-10,449	Closed	-$192K	–	13547
2023 Q4	$192K	Buy	10,449 +8,474	+429%	+$140K	﹤0.01%	10729
2023 Q3	$34.3K	Buy	+1,975	New	+$34.3K	﹤0.01%	11435
2023 Q2	–	Sell	-9,064	Closed	-$181K	–	13318
2023 Q1	$155K	Buy	9,064 +4,259	+89%	+$68.9K	﹤0.01%	10878
2022 Q4	$112K	Buy	+4,805	New	+$111K	﹤0.01%	10857

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Susquehanna International Group's LENZ Position: Q1 2026 in Review

Susquehanna International Group increased its LENZ Therapeutics (LENZ) stake by 63% in Q1 2026, buying an estimated $598K and bringing the position to 110,304 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #7852.

Susquehanna International Group first reported a position in LENZ in Q4 2022 and has held it in 10 quarters since. The position peaked at $2.35M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

Susquehanna International Group held 110,304 shares of LENZ Therapeutics worth $1.01M as of Q1 2026.
Susquehanna International Group bought 42,582 LENZ Therapeutics shares in Q1 2026, an estimated $598K.
LENZ Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7852 holding.
Susquehanna International Group first reported a position in LENZ Therapeutics in Q4 2022 and has held it in 10 quarters since.
Susquehanna International Group's LENZ Therapeutics position peaked at $2.35M in Q3 2025.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.